成人与儿童原发纵隔B细胞淋巴瘤接受剂量调整EPOCH-R治疗的结局
这项多中心回顾性分析纳入24个学术中心的156例原发纵隔B细胞淋巴瘤患者(38例儿童、118例成人),均接受至少1周期DA-EPOCH-R。中位随访22.6个月,估计3年无事件生存率为85.9%(95%CI 80.3-91.5),总生存率为95.4%(95%CI 91.8-99.0),儿童与成人结局无统计学差异;治疗结束FDG-PET阴性者无事件生存更优。
要点
- 24个学术中心156例PMBCL患者接受DA-EPOCH-R,含38例儿童和118例成人。
- 估计3年无事件生存率85.9%(95%CI 80.3-91.5),总生存率95.4%(95%CI 91.8-99.0)。
- 治疗结束FDG-PET阴性者无事件生存优于阳性者(95.4% vs 54.9%,P<0.001)。
核心结论
- 数据支持DA-EPOCH-R用于儿童和成人PMBCL的治疗。
- 治疗结束FDG-PET阳性的患者结局较差。
研究设计与样本
- 多中心回顾性分析,纳入24个学术中心156例PMBCL患者,包括38例儿童和118例成人。
- 所有患者接受至少1周期DA-EPOCH-R(依托泊苷、多柔比星、环磷酰胺、长春新碱、泼尼松联合利妥昔单抗)。
- 14.9%的患者接受了放疗。
主要发现
- 中位随访22.6个月,估计3年无事件生存率为85.9%(95%CI 80.3-91.5),总生存率为95.4%(95%CI 91.8-99.0)。
- 儿童与成人患者的结局无统计学差异。
- 血栓并发症发生率为28.2%,儿童患者更常见(45.9% vs 22.9%,P=0.011)。
- 75%的患者在DA-EPOCH-R结束时FDG-PET阴性,定义为Deauville评分1-3。
- 治疗结束FDG-PET阴性与无事件生存改善相关(95.4% vs 54.9%,P<0.001)。
关键数值与推荐
- 治疗结束FDG-PET阴性定义为Deauville评分1-3。
- 治疗结束FDG-PET阴性者估计无事件生存率95.4%,阳性者54.9%(P<0.001)。
临床怎么用
- 作者认为数据支持DA-EPOCH-R用于儿童和成人PMBCL的治疗。
- 作者指出治疗结束FDG-PET阳性的患者结局较差。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in the multi-centre setting. We report a large, multi-centre retrospective analysis of children and adults with PMBCL treated with DA-EPOCH-R to characterize outcomes and evaluate prognostic factors. We assessed 156 patients with PMBCL treated with DA-EPOCH-R across 24 academic centres, including 38 children and 118 adults. All patients received at least one cycle of DA-EPOCH-R. Radiation therapy was administered in 14·9% of patients. With median follow-up of 22·6 months, the estimated 3-year event-free survival (EFS) was 85·9% [95% confidence interval (CI) 80·3-91·5] and overall survival was 95·4% (95% CI 91·8-99·0). Outcomes were not statistically different between paediatric and adult patients. Thrombotic complications were reported in 28·2% of patients and were more common in paediatric patients (45·9% vs. 22·9%, P = 0·011). Seventy-five per cent of patients had a negative fluorodeoxyglucose positron emission tomography (FDG-PET) scan at the completion of DA-EPOCH-R, defined as Deauville score 1-3. Negative FDG-PET at end-of-therapy was associated with improved EFS (95·4% vs. 54·9%, P < 0·001). Our data support the use of DA-EPOCH-R for the treatment of PMBCL in children and adults. Patients with a positive end-of-therapy FDG-PET scan have an inferior outcome.
引用
- Giulino-Roth L, O'Donohue T, Chen Z, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017. PMID: 29082519. doi:10.1111/bjh.14951
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。